fig8

Figure 8. NUPR1 increases TEV release and packages NUPR1 in TEVs to promote cancer progression. (A) Western blot analysis for NUPR1 using 10 µg of EO771 TEVs isolated from 2 separate collections 24 hrs after cells were treated with vehicle, 10 µM reserpine, or 100 µM paclitaxel; (B) RNAseq analysis of EV markers using RNA from normal human lung bronchial epithelial cells BEAS-2B and BEAS-2B engineered to overexpress NUPR1; (C) Nanoparticle tracking analysis of TEVs from nickel transformed BEAS-2B cells and nickel transformed BEAS-2B cells expressing shRNA for NUPR1; (D) Western blot analysis for NUPR1 in EVs from nickel transformed BEAS-2B cells and nickel transformed BEAS-2B cells expressing shRNA for NUPR1. The EVs were further characterized for EV markers CD63 and GAPDH and the non EV biomarker GM130; (E) NUPR1 RNA expression from mouse Ch25h^-/- endothelial cells treated with vehicle, TEV, or TEV with 10 µM reserpine. TEVs: Tumor-derived extracellular vesicles; NUPR1: Nuclear protein 1; EV: Extracellular vesicle.